# Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction

> **NCT04128891** · PHASE3 · WITHDRAWN · sponsor: **Flinders University**

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Sacubitril-Valsartan

## Key facts

- **NCT ID:** NCT04128891
- **Lead sponsor:** Flinders University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02-01
- **Primary completion:** 2020-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding not approved
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04128891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04128891, "Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04128891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*